ELTP Financials 07/15/2014 21:59:20
Elite Pharmaceuticals, Inc.
Period Ending Mar 31, 2014 Mar 31, 2013 Mar 31, 2012 Mar 31, 2011
Total Revenue 4,601 3,404 2,424 4,266
Cost of Revenue 3,236 2,315 1,014 2,675
Gross Profit 1,365 1,088 1,410 1,591
Operating Expenses
Research and Development 3,959 975 1,736 1,385
Sales, General and Admin. 2,189 1,559 1,435 918
Non-Recurring Items - - - -
Other 501 117 206 173
Operating Income (5,284) (1,563) (1,966) (886)
Income From Continuing Operations
Add'l Income/Expense Items (90,684) 3,090 (12,922) (11,507)
Earnings Before Interest and Tax (95,968) 1,527 (14,888) (12,392)
Interest Expense 900 393 654 1,491
Earnings Before Tax (96,868) 1,134 (15,542) (13,884)
Income Tax (293) (354) (484) (301)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (96,575) 1,488 (15,058) (13,582)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (96,575) 1,488 (15,058) (13,582)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (96,575) 1,488 (15,058) (13,582)